anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A vaccine that has been synthesized by a polyvalent substrate and the idiotype parts of antibodies that recognize antimetastatic peptides. The vaccine induces the production of antiidiotype antibodies that inhibit metastasis formation. It is known that the ability of a cancer cell to metastasize is primary dependent by its property to bind with extracellular matrix proteins such as laminin and fibronectin. On these proteins the antimetastatic sequences (peptides) YIGSR and RGD have been discovered since 1991. Attempts to use these peptides either per se or as constituents of polymers in order to inhibit spontaneous metastasis in experimental animals had only limited results because of the limited life time of these preparation in the circulation. Using the described vaccine the immune system is leaded to the production of antiidiotype antibodies that have shape and properties similar to the antimetastatic peptides YIGSR and RGD. Pilot experiments indicated that these antibodies can inhibit the formation of spontaneous metastasis in experimental animals.
ETHNOPHARMACOLOGICAL RELEVANCE: Sea buckthorn (Hippophae rhamnoides), a traditional Tibetan medicinal herb, exhibits protective effects against cardiovascular and respiratory diseases. Although Sea buckthorn extract (SBE) has been confirmed to alleviate airway inflammation in mice, its therapeutic effect and underlying mechanism on chronic obstructive pulmonary disease (COPD) requires further clarification.
AIM OF THE STUDY: To elucidate the alleviative effect and molecular mechanism of SBE on lipopolysaccharides (LPS)/porcine pancreatic elastase (PPE)-induced COPD by blocking ferroptosis.
METHODS: The anti-ferroptotic effects of SBE were evaluated in human BEAS-2B bronchial epithelial cells using CCK8, RT-qPCR, western blotting, and transmission electron microscopy. Transwell was employed to detect chemotaxis of neutrophils. COPD model was induced by intranasally administration of LPS/PPE in mice and measured by alterations of histopathology, inflammation, and ferroptosis. RNA-sequencing, western blotting, antioxidant examination, flow cytometry, DARTS, CETSA, and molecular docking were then used to investigate its anti-ferroptotic mechanisms.
RESULTS: In vitro, SBE not only suppressed erastin- or RSL3-induced ferroptosis by suppressing lipid peroxides (LPOs) production and glutathione (GSH) depletion, but also suppressed ferroptosis-induced chemotactic migration of neutrophils via reducing mRNA expression of chemokines. In vivo, SBE ameliorated LPS/PPE-induced COPD phenotypes, and inhibited the generation of LPOs, cytokines, and chemokines. RNA-sequencing showed that p53 pathway and mitogen-activated protein kinases (MAPK) pathway were implicated in SBE-mediated anti-ferroptotic action. SBE repressed erastin- or LPS/PPE-induced overactivation of p53 and MAPK pathway, thereby decreasing expression of diamine acetyltransferase 1 (SAT1) and arachidonate 15-lipoxygenase (ALOX15), and increasing expression of glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11). Mechanistically, erastin-induced elevation of reactive oxygen species (ROS) was reduced by SBE through directly scavenging free radicals, thereby contributing to its inhibition of p53 and MAPK pathways. CETSA, DARTS, and molecular docking further showed that ROS-generating enzyme nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4 (NOX4) may be the target of SBE. Overexpression of NOX4 partially impaired the anti-ferroptotic activity of SBE.
CONCLUSION: Our results demonstrated that SBE mitigated COPD by suppressing p53 and MAPK pro-ferroptosis pathways via directly scavenging ROS and blocking NOX4. These findings also supported the clinical application of Sea buckthorn in COPD therapy.
BACKGROUND: The introduction of biologic therapies and the 'treat-to-target' treatment strategy may have changed the disease course of ulcerative colitis (UC).
AIMS: To describe the early disease course and disease outcome at 1-year follow-up in a population-based inception cohort of adult patients with newly diagnosed UC.
METHODS: The Inflammatory Bowel Disease in South-Eastern Norway (IBSEN) III study is a population-based inception cohort study with prospective follow-up. Patients newly diagnosed with inflammatory bowel disease during 2017-2019 were included. Patients ≥18 years at diagnosis of UC who attended the 1-year follow-up were investigated. We registered clinical, endoscopic and demographic data at diagnosis and 1-year follow-up.
RESULTS: We included 877 patients with UC (median age 36 years (range: 18-84), 45.8% female). At diagnosis, 39.2% presented with proctitis, 24.7% left-sided colitis and 36.0% extensive colitis. At the 1-year follow-up, 13.9% experienced disease progression, and 14.5% had received one or more biologic therapies. The colectomy rate was 0.9%. Steroid-free clinical remission was observed in 76.6%, and steroid-free endoscopic remission in 68.7%. Anaemia and initiation of systemic steroid treatment at diagnosis were associated with biologic therapy within the first year after diagnosis.
CONCLUSION: In this population-based inception cohort, colectomy rate in the first year after diagnosis was low, and a high proportion of patients were in remission at 1-year follow-up. The use of biologic therapy increases, consistent with findings from previous studies.
1. Investigate H-CEUS abnormalities in microcirculation at DFU ulcer sites Conduct H-CEUS detection of blood vessels at ulcer sites for each participant. Qualitatively and quantitatively analyze differences in contrast enhancement time, intensity, uniformity, direction, and vessel morphology among different patient groups based on time-intensity curves. Compare H-CEUS indicators between DFU ulcer and normal sites, followed by single-factor and multi-factor logistic regression analysis to identify meaningful imaging indicators for diagnosing DFU and construct an H-CEUS score.
2. Correlate H-CEUS score with traditional measurement indicators Perform color Doppler ultrasound (CDU), laser Doppler perfusion monitoring (LDPM), and transcutaneous partial pressure of oxygen (TcPO2) measurements at ulcer sites for participants. Analyze the correlation between H-CEUS score and the aforementioned five traditional microcirculation assessment methods. This analysis aims to determine if H-CEUS effectively reflects the degree of ischemia in DFU patients' ulcerated limbs, providing a new, non-invasive assessment tool to assist physicians in accurately assessing ulcer severity and tissue damage, facilitating the formulation of individualized and effective treatment plans.
3. Construct and evaluate the limb salvage predictive model using H-CEUS Conduct a retrospective analysis of clinical data from hospitalized DFU patients, categorizing them into limb salvage and amputation groups. Compare baseline data, biochemical indicators, and data based on H-CEUS scores between the two groups. Utilize single-factor and multi-factor logistic regression analysis to identify amputation-related risk factors. Subsequently, employ a random forest algorithm to construct a model based on H-CEUS data to predict limb salvage in DFU patients. To further validate the accuracy and clinical utility of this predictive model, nomogram charts and decision curve analysis (DCA) will be created.
Children in this arm will receive lipid-based nutrient supplements (LNS) for 12-18 months. LNS are 20 g/\~110 calorie nutrient supplements that provide energy, protein, essential fatty acids and a wide range of micronutrients critical for children ages 6 to 24 months of age. They are designed to complement diets without displacing breastmilk and local dietary preferences and can be mixed into the child's meal or eaten directly from the sachet. The LNS used in this study will be Nutributter plus.
The specimen was preferentially extracted via a small Pfannenstiel-type incision with the protection of an Alexis Wound Protector (Applied Medical, Rancho Santa Margarita, California, USA). The incision for the extraction of the right colon is sutured in two layers by absorbable suture. The ileum was held by the assistant to prevent rotation of its mesentery. A stay suture was applied 10 cm proximal and distal to the stapled ends of the terminal ileum and colon, respectively, and then held by the assistant. An enterotomy and colotomy were made sharply at the antimesenteric corner of the staple lines. An isoperistaltic side-to-side anastomosis was fashioned with a 60-mm laparoscopic stapler. A 2-0 double-barbed suture was used to close the enterocolotomy, in two planes (the first submucosal, and the second sero-serous). The mesenteric defect and the mesocolon after the construction of either type of anastomosis were not closed. Drains were not used routinely.
PURPOSE OF REVIEW: The global obesity epidemic has become a major public health concern, necessitating comprehensive research into its adverse effects on various tissues within the human body. Among these tissues, skeletal muscle has gained attention due to its susceptibility to obesity-related alterations. Mitochondria are primary source of energy production in the skeletal muscle. Healthy skeletal muscle maintains constant mitochondrial content through continuous cycle of synthesis and degradation. However, obesity has been shown to disrupt this intricate balance. This review summarizes recent findings on the impact of obesity on skeletal muscle mitochondria structure and function. In addition, we summarize the molecular mechanism of mitochondrial quality control systems and how obesity impacts these systems. RECENT FINDINGS: Recent findings show various interventions aimed at mitigating mitochondrial dysfunction in obese model, encompassing strategies including caloric restriction and various dietary compounds. Obesity has deleterious effect on skeletal muscle mitochondria by disrupting mitochondrial biogenesis and dynamics. Caloric restriction, omega-3 fatty acids, resveratrol, and other dietary compounds enhance mitochondrial function and present promising therapeutic opportunities.
Inflammation-related diseases are often marked by elevated levels of nitric oxide (NO) and reactive oxygen species (ROS), which play important roles in the modulation of inflammation. However, the development of organic materials effective in managing NO/ROS levels has remained a challenge. This study introduces a novel organic compound, NmeGA, engineered to scavenge both NO and ROS. NmeGA ingeniously integrates N-methyl-1,2,-phenylenediamine (Nme), a NO scavenger, with gallic acid (GA), a ROS scavenger, through an amide bond, endowing it with enhanced scavenging capabilities over its individual component. This compound exhibits reduced toxicity and increased lipophilicity value, underlining its increased biological applicability and highlighting its potential as an inflammation management tool. Through in vitro studies on lipopolysaccharide (LPS)-stimulated RAW 264.7 cells, NmeGA displayed remarkable scavenging efficiency for NO and ROS, coupled with significant anti-inflammatory effects. In an LPS-induced peritonitis model, administration of NmeGA substantially decreased mortality rates, NO and ROS levels, and inflammatory cytokine concentrations. These findings highlight NmeGA's versatility as a therapeutic agent against various inflammatory diseases.
Adults with chronic kidney disease (CKD) tend to be extremely sedentary. We investigated the feasibility and acceptability of a sedentary-reducing intervention for adults with CKD. The intervention utilized telephone-delivered coaching and a consumer wearable device to support participants to reduce their sedentary time. The mean age of participants in the sample was 60.5 years; 72% were women, and 83% had CKD Stage 3. At baseline, participants spent 73% of their waking time sedentary. Inter vention phone call attendance was 100%, study retention was 82%, and the intervention was rated as enjoyable (9.1/10). A telephone-delivered, sedentary-reducing intervention is feasible and acceptable in adults with CKD. Future work is needed investigating the efficacy of sedentary-reducing interventions for adults with CKD.
Treatment was based on the CBT approach and previous literature about FOD. It consisted of 12 weekly online individual sessions, which were administered once a week (total duration = 3 months) and lasted about 60 minutes each.
Provided is a traditional Chinese medicine composition for treating bladder damp-heat type stranguria. The traditional Chinese medicine composition is prepared from sunset abelmoschus roots, common joyweed, viburnum cylindricum Buch. Ham. ex D. don, Chinese bastardtoadflax herbs, all-grass of Japanese climbing ferns, leaves of clammy hopseedbush, carpinus cordata B1.var.chinensis Franch., bulbophyllum psychoon Reichb. f., longstamen onion bulbs and rhizome of giantreed. The traditional Chinese medicine composition can be used for treating the bladder damp-heat type stranguria in clinic.
The safety and efficacy of LEVULAN KERASTICK topical solution plus BLU-U Blue Light Photodynamic Therapy Illuminator at 10J/cm 2to treat actinic keratoses of the upper extremities has been evaluated in a multicenter randomized, parallel-group, evaluator-blinded, vehicle-controlled trial of 269 subjects. 

In this trial (CP0108), 269 subjects with 4 -15 mild to moderate actinic keratoses on the upper extremities (dorsal hand/forearm area between the elbow and the base of the fingers) were treated with LEVULAN KERASTICK topical solution and BLU-U Blue Light Photodynamic Therapy Illuminator. Subjects ranged from 45 to 90 years of age (mean 68 years) and 90% had Fitzpatrick Skin Type I, II or III. No subjects had Fitzpatrick Skin Type V or VI. Approximately 70% of subjects were male and all subjects were Caucasian.

Subjects were randomized to treatment in a 1:1 ratio to receive either LEVULAN KERASTICK topical solution or vehicle. Treatment was applied to 4-15 lesions on one dorsal hand/forearm on each subject, and occluded for the three-hour incubation period before treatment with 10 J/cm 2blue light delivered at 10 mW/cm 2. Treatment was repeated at Week 8 if any actinic keratosis lesions were present in the treatment area. 

The primary endpoint was the proportion of subjects with complete clearance of all actinic keratosis lesions in the treatment area 12 weeks after initial treatment. The results of the trial are presented in Table 8. 

Subject outcomes recorded in the trial of the upper extremities are depicted in the following flowchart.

Subjects who achieved complete clearance at Week 12 entered a 12-month follow-up period. Subjects who received LEVULAN KERASTICK topical solution with blue light and achieved complete clearance at Week 12 in CP0108A had a recurrence rate of 58% (22/38) at 12 months, where recurrence was defined as the presence of at least one previously treated lesion in the treatment area at any visit during the 12-month follow-up period.
The invention discloses an N-acyl group modified sialic acid (alpha-(2-6))-D-amino pyranose derivative and its synthetic method and use. The sialic acid (alpha-(2-6))-D-amino pyranose derivative shown in the formula (I) is synthesized from raw materials of D-galactosamine (glucose) and sialic acid and is coupled with a carrier protein or a polypeptide to form a glycoprotein (glycopeptide) conjugate. In a structure of the N-acyl group modified sialic acid (alpha-(2-6))-D-amino pyranose derivative, a derivative acyl group replaces an acetyl group and thus the structure is novel. The N-acyl group modified sialic acid (alpha-(2-6))-D-amino pyranose derivative has good activity in anti-tumor vaccines. A result of an experiment on mice shows that through structural derivatization, a carbohydrate antigen based vaccine can produce an effective immune response and a mass of antibodies and IgG/IgM is improved obviously. The antibodies can identify specifically tumor cells expressing STn and thus anti-tumor effects are realized. STn antigens can be expressed on multiple tumors and thus the N-acyl group modified sialic acid (alpha-(2-6))-D-amino pyranose derivative has a wide application scope.
The invention discloses apricot flower pure grain health wine, and belongs to the technical field of health products. The wine is characterized by being brewed from the following raw materials in parts by weight: the pure grain liquor brewed by taking pure grains as raw materials comprises 100-1000 parts of wine base, 1-10 parts of apricot flowers and 1-5 parts of apricot pollen. The apricot flower and pure grain health wine takes pure grain white spirit brewed by taking pure grain as a raw material as a wine base, and is matched with apricot flowers and pollen thereof, so that the apricot flower and pure grain health wine has pure grade, mellow taste and aromatic flavor; and has effects of caring skin, invigorating spleen and replenishing qi, dispelling pathogenic wind, dredging collaterals, building body and prolonging life. The invention has better taste, can promote blood circulation after long-term use, and leads users to be full of energy and have ruddy and smooth skin. The invention can be directly drunk by people, and simultaneously achieves the purposes of treating diseases and preventing diseases without diseases. The apricot flower pure grain health-care wine has the advantages of simple brewing process, low production cost, suitability for popularization and high commercial value.
Background: The 2019 novel coronavirus, belonging to the β species of coronaviruses, primarily spreads through respiratory droplets and close contact. Even after recovering from the infection, COVID-19 can lead to various chronic health issues, with impaired lung function, reduced exercise performance, and diminished quality of life being prevalent among a significant proportion of patients. In Bangladesh, post-COVID-19 patients represent a considerable population who have overcome the acute phase of the infection but continue to face numerous social, psychological, and physical challenges. Among these challenges, respiratory complications such as persistent cough, shortness of breath, and decreased lung function are frequently observed in post-COVID-19 patients in Bangladesh. In addition, these individuals often experience fatigue, muscle weakness, and joint pain. These physical symptoms can profoundly impact their daily activities and overall quality of life, necessitating ongoing medical care and rehabilitation.

Purpose: To evaluate the efficacy of pulmonary rehabilitation in post-COVID-19 patients and to compare differences in outcomes between before and after pulmonary rehabilitation Methodology: It will be a hospital-based quasi-experimental study. The investigator will conveniently select adult post-COVID-19 patients whose respiratory symptoms (fatigue, exertional dyspnea, etc.) persist longer than 12 weeks from the onset of their first symptoms from outpatient and inpatient of the Department of Respiratory Medicine, Bangabandhu Sheikh Mujib Medical University. Participants will participate in a 06-weeks (Two sessions per week) comprehensive multimodal and multidisciplinary outpatient pulmonary rehabilitation. In-person interviews will be done for data collection. The total sample size will be 130. Before the study, the research protocol will be approved by the Institutional Review Board (IRB) of Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka.

Expected outcome: The study's findings will reveal the benefits of pulmonary rehabilitation among post-COVID-19 patients.
Participants will receive the standard prenatal care and invited to participate of a breastfeeding workshop during the third trimester of pregnancy, with active and intentional participation of the pregnant woman and her partner/relative; based on adult education methodology. In addition, women participants will have continuous support during their breastfeeding process, up to 6 months of the child's life, through a virtual support group (whats-app), where they will receive messages that promote their self-efficacy in relation to their ability to breastfeed and may ask questions that are related to breastfeeding. Professionals in this group will be train before delivering the intervention.
The invention discloses a traditional Chinese medicine-Western medicine synthetic medicament for treating gastric ulcer. The traditional Chinese medicine-Western medicine synthetic medicament is mainly prepared from ammophila arenaria, alum, greater celandine herb, pinellia tuber, spanishneedles herb, wild chrysanthemum plant, pinellia tuber, mongolian snakegourd and giant knotweed rhizome. A Western medicine formula consists of procaine hydrochloride, metronidazole, motrin, gastric mucin, aluminum hydroxide, veylalo tablet, vitamin B1 and vitamin B2. The medicament is prepared by compounding a traditional Chinese medicine and a Western medicine, has no toxic or side effect, has mild nature, and is not cold or hot. The traditional Chinese medicine-Western medicine synthetic medicament has remarkable ulcer treatment effect, good curative effect, short course of treatment, small dosage, low cost, is safe and convenient to take, is easy and convenient to prepare, and is an effective prescription for treating gastric ulcer. Years of clinical experience indicate that the curative ratio of the medicament is over 90 percent and the effective rate is 100 percent.
FIELD: medicine, pulmonology, toxicology. SUBSTANCE: method involves administration of 5% solution of mexidol in the dose 400 mg, 2 times per 24 h with interval for 12 h for 3-5 days by intravenous drop route. If necessary, the pneumonia treatment with mexidol is continued in the dose 200 mg, 2 times per 24 h for 3-4 days additionally. Invention provides to reduce frequency of the development of pulmonary inflammatory processes, pneumonia duration and diminish lethality in patients with acute exogenous intoxications. EFFECT: improved method of treatment and prophylaxis. 2 cl, 1 tbl, 6 ex
PURPOSE: To obtain a starburst conjugate by the reaction of a starburst dendrimer with a carrier material. CONSTITUTION: A starburst conjugate expressed by the formula (P)X*(M)Y, wherein P is a dendrimer, x is >=1, M is a pharmaceutical substance unit deposited, y is >=1, and * represents association of the carried pharmaceutical substance with the dendrimer, is obtd. by the reaction of P and M in a solvent (such as water and methanol) at room temp. to the refluxing temp. of the solvent. The starburst conjugate is suitable to release the substance carried at high concn. per the polymer unit, to release under control and to release a target or various kinds.
Patients with confirmed primary endometrioid adenocarcinoma eligible for first line curative surgery will receive celecoxib 400 mg twice a day, for 15 days before the curative surgery for their endometrial cancer. The patients will undergo an endometrial biopsy at the inclusion and during the surgery.
A 35-year-old woman at 36 weeks and 4 days gestation with known complete anterior placenta previa and no other medical history presented for routine obstetric follow-up. She reported increasing fatigue in the prior week but otherwise endorsed no new concerns. She denied recent vaginal bleeding or discharge, abdominal pain, contractions, or extremity swelling. On evaluation, her BP was 126/74 mm Hg with a heart rate of 72 beats per min. The results from the physical examination were normal. There was a category II fetal heart rate tracing and a 6/10 biophysical profile (ie, no fetal breathing movements, nonreactive nonstress test), which prompted referral to the hospital. On admission, sonogram confirmed cephalic presentation and redemonstrated complete anterior placenta previa with no evidence of hemorrhage. She received antenatal steroids and was scheduled for a cesarean section delivery. She received bupivacaine spinal anesthesia for the procedure. The surgical procedure progressed with a low transverse uterine incision and subsequent delivery of the baby with no complications noted. Immediately after delivery of the baby and during gentle traction of the placenta, the patient experienced rapid cardiovascular collapse in the form of hypotension and bradycardia.